Acute Ischemic Stroke

Biopharma company to start phase IIa study with neuroprotectant Enecadin in acute ischemic stroke

Published in Medical Letter on the CDC and FDA, March 12th, 2006

Paion (PA8.DE) announced that it has received formal authorization by the German regulatory authority Bundesinstitut fuer Arzneimittel und Medizinprodukte (BfArM) to commence the clinical phase IIa study tolerability of Enecadin in acute ischemic stroke trial (TEST) with Paion's neuroprotectant Enecadin.

The study was previously approved by the responsible Ethics Committee of Heidelberg University Hospital.

Enecadin is a neuroprotective sodium and calcium channel blocker. It has been extensively studied in various in vivo models examining pharmacokinetic and pharmacodynamic parameters and with respect to safety and toxicity. It has shown excellent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-03-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry